1. Rokit Healthcare H1 2025 Performance: A Mixed Bag

Rokit Healthcare achieved KRW 9.708 billion in revenue in the first half of 2025, with Q2 revenue reaching KRW 6 billion, a 62.16% surge compared to Q1. However, the company remains in the red operationally, with net losses widening to KRW -0.9 billion. Accumulated deficit reached a concerning KRW 110.189 billion.

2. Positive Factors: Innovative Technology and Global Expansion

Rokit Healthcare’s core strength lies in its AI-driven, patient-customized organ regeneration platform. Securing key regulatory approvals like CE MDR, FDA, and MFDS validates its technology and signals positive prospects for European and US market penetration. Furthermore, the company successfully raised capital through its KOSDAQ listing and convertible bond issuance.

3. Negative Factors: Persistent Losses and Financial Instability

Despite revenue growth, persistent net losses remain a critical issue. High selling, general, and administrative expenses (SG&A), foreign exchange risks, and negative cash flow from investing activities raise concerns about financial health. While the convertible bond issuance provides funding, it carries the risk of future share dilution.

4. Key Investor Checkpoints

  • Sustainable Revenue Growth: Can Rokit maintain its impressive Q2 momentum?
  • Profitability Prospects: Scrutinize cost optimization and plans for achieving profitability.
  • Financial Risk Management: Assess the company’s strategies for mitigating financial risks, including foreign exchange fluctuations and debt levels.

5. Conclusion: Potential and Risk Coexist, Invest with Caution

Rokit Healthcare possesses innovative technology and growth potential, but its financial instability demands a cautious investment approach. Careful monitoring of future earnings releases and execution of business plans is crucial for informed investment decisions.